CN104865307A - Analysis method for alcohol compound in biological sample - Google Patents
Analysis method for alcohol compound in biological sample Download PDFInfo
- Publication number
- CN104865307A CN104865307A CN201510164576.6A CN201510164576A CN104865307A CN 104865307 A CN104865307 A CN 104865307A CN 201510164576 A CN201510164576 A CN 201510164576A CN 104865307 A CN104865307 A CN 104865307A
- Authority
- CN
- China
- Prior art keywords
- carboxylic acid
- analysis
- quinoline
- matrix
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012472 biological sample Substances 0.000 title claims abstract description 12
- 238000004458 analytical method Methods 0.000 title claims description 22
- -1 alcohol compound Chemical class 0.000 title claims description 8
- 238000004252 FT/ICR mass spectrometry Methods 0.000 claims abstract description 33
- 150000001298 alcohols Chemical class 0.000 claims abstract description 26
- 239000011159 matrix material Substances 0.000 claims abstract description 23
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000000523 sample Substances 0.000 claims abstract description 16
- 238000004451 qualitative analysis Methods 0.000 claims abstract description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 18
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 12
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 12
- 235000012000 cholesterol Nutrition 0.000 claims description 12
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 238000001228 spectrum Methods 0.000 claims description 11
- 210000005253 yeast cell Anatomy 0.000 claims description 11
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 claims description 9
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 claims description 9
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 claims description 7
- 230000002538 fungal effect Effects 0.000 claims description 5
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 4
- 239000012044 organic layer Substances 0.000 claims description 4
- VQMSRUREDGBWKT-UHFFFAOYSA-N quinoline-4-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=NC2=C1 VQMSRUREDGBWKT-UHFFFAOYSA-N 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 claims description 3
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 claims description 3
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 claims description 3
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 claims description 3
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 claims description 3
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 claims description 3
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 claims description 3
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 claims description 3
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 claims description 3
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 claims description 3
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- 229940061641 androsterone Drugs 0.000 claims description 3
- UCTLRSWJYQTBFZ-DDPQNLDTSA-N cholesta-5,7-dien-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC=C21 UCTLRSWJYQTBFZ-DDPQNLDTSA-N 0.000 claims description 3
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 claims description 3
- 210000002768 hair cell Anatomy 0.000 claims description 3
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 claims description 3
- 229940058690 lanosterol Drugs 0.000 claims description 3
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 claims description 3
- 235000016831 stigmasterol Nutrition 0.000 claims description 3
- 229940032091 stigmasterol Drugs 0.000 claims description 3
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 claims description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 3
- 235000005282 vitamin D3 Nutrition 0.000 claims description 3
- 239000011647 vitamin D3 Substances 0.000 claims description 3
- 229940021056 vitamin d3 Drugs 0.000 claims description 3
- 229940107161 cholesterol Drugs 0.000 claims description 2
- 238000007405 data analysis Methods 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- RAYMXZBXQCGRGX-UHFFFAOYSA-N quinoline-5-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=N1 RAYMXZBXQCGRGX-UHFFFAOYSA-N 0.000 claims description 2
- WXXVQWSDMOAHHV-UHFFFAOYSA-N quinoline-7-carboxylic acid Chemical compound C1=CC=NC2=CC(C(=O)O)=CC=C21 WXXVQWSDMOAHHV-UHFFFAOYSA-N 0.000 claims description 2
- QRDZFPUVLYEQTA-UHFFFAOYSA-N quinoline-8-carboxylic acid Chemical compound C1=CN=C2C(C(=O)O)=CC=CC2=C1 QRDZFPUVLYEQTA-UHFFFAOYSA-N 0.000 claims description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 2
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 238000007127 saponification reaction Methods 0.000 claims 1
- 238000001212 derivatisation Methods 0.000 abstract description 11
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 7
- 238000001514 detection method Methods 0.000 abstract description 4
- 238000004949 mass spectrometry Methods 0.000 abstract description 4
- 239000012491 analyte Substances 0.000 abstract description 2
- 238000004648 ion cyclotron resonance mass spectroscopy Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 7
- 231100000640 hair analysis Toxicity 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 229930182558 Sterol Natural products 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 206010048676 Sjogren-Larsson Syndrome Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- SXKNCCSPZDCRFD-UHFFFAOYSA-N betaine aldehyde Chemical compound C[N+](C)(C)CC=O SXKNCCSPZDCRFD-UHFFFAOYSA-N 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- KLAKIAVEMQMVBT-UHFFFAOYSA-N p-hydroxy-phenacyl alcohol Natural products OCC(=O)C1=CC=C(O)C=C1 KLAKIAVEMQMVBT-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical compound NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- VXGYRCVTBHVXMZ-UHFFFAOYSA-N quinoline-6-carboxylic acid Chemical compound N1=CC=CC2=CC(C(=O)O)=CC=C21 VXGYRCVTBHVXMZ-UHFFFAOYSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
本发明涉及一种生物样本中醇类化合物的靶上衍生化-基质辅助激光解析-傅立叶变换离子回旋共振质谱(MALDI-FT ICR MS)定性分析方法,此方法包括下列步骤:目标分析物经样本前处理;以喹啉羧酸为衍生化试剂和基质,在质谱的靶板上与醇类化合物反应,生成衍生化产物,同时过量喹啉羧酸为基质,再经基质辅助激光解析-傅立叶变换离子回旋共振质谱定性分析。该方法快速、高效、灵敏,为醇类化合物检测奠定基础。
The invention relates to a qualitative analysis method of on-target derivatization-matrix-assisted laser analysis-Fourier transform ion cyclotron resonance mass spectrometry (MALDI-FT ICR MS) for alcohol compounds in biological samples. The method comprises the following steps: the target analyte is passed through the sample Pretreatment: use quinoline carboxylic acid as derivatization reagent and matrix, react with alcohol compounds on the target plate of mass spectrometry to generate derivatized products, and at the same time, excess quinoline carboxylic acid as matrix, and then undergo matrix-assisted laser analysis-Fourier transform Qualitative analysis by ion cyclotron resonance mass spectrometry. The method is fast, efficient and sensitive, and lays the foundation for the detection of alcohols.
Description
技术领域technical field
本发明涉及一种醇类化合物的靶上衍生化-基质辅助激光解析质谱-傅立叶变换离子回旋共振质谱(MALDI-FT ICR MS)分析方法,其特征是以喹啉羧酸为衍生化试剂和基质,在质谱的靶板上与醇类化合物反应,生成衍生化产物,同时过量喹啉羧酸为基质,从而提高MALDI离子化效率,经基质辅助激光解析-傅立叶变换离子回旋共振质谱分析醇类化合物。The present invention relates to a kind of on-target derivatization-matrix-assisted laser analysis mass spectrometry-Fourier transform ion cyclotron resonance mass spectrometry (MALDI-FT ICR MS) analysis method of alcohol compounds, which is characterized in that quinoline carboxylic acid is used as derivatization reagent and matrix , react with alcohol compounds on the target plate of the mass spectrometer to generate derivatized products, and at the same time, excess quinoline carboxylic acid is used as the matrix to improve the ionization efficiency of MALDI, and the alcohol compounds are analyzed by matrix-assisted laser analysis-Fourier transform ion cyclotron resonance mass spectrometry .
背景技术Background technique
醇类化合物如胆固醇、脂肪醇、维生素A、类固醇激素、麦角甾醇等是人体内重要的代谢物和抗真菌药物作用靶点,与多种代谢酶的功能相关。这些化合物的含量变化可以反应疾病和人体内代谢酶的异常,例如,人体内胆固醇含量变化与阿尔茨海默病,冠心病等多种疾病相关;人体中脂肪醇含量与Sjogren-Larsson综合症,DHAP合酶缺乏等疾病相关;真菌细胞的甾醇代谢是抗真菌药物作用靶点和真菌耐药机制之一。因此,对生物样本(如血浆,尿液、毛发、细胞)中醇类化合物进行定性和定量分析对研究许多生理变化、疾病诊断和药物筛选有非常重要的作用。Alcohol compounds such as cholesterol, fatty alcohols, vitamin A, steroid hormones, and ergosterol are important metabolites and targets of antifungal drugs in the human body, and are related to the functions of various metabolic enzymes. Changes in the content of these compounds can reflect diseases and abnormal metabolic enzymes in the human body. For example, changes in cholesterol content in the human body are related to Alzheimer's disease, coronary heart disease and other diseases; fatty alcohol content in the human body is related to Sjogren-Larsson syndrome, DHAP synthase deficiency and other diseases are related; the sterol metabolism of fungal cells is the target of antifungal drugs and one of the mechanisms of fungal drug resistance. Therefore, the qualitative and quantitative analysis of alcohol compounds in biological samples (such as plasma, urine, hair, cells) plays a very important role in the study of many physiological changes, disease diagnosis and drug screening.
生物样本(如尿液、毛发、细胞)中醇类化合物的分析方法主要是高效液相色谱-质谱(LC-MS)和气相色谱-质谱(GC-MS),但前处理较复杂,需要分离纯化,不能满足高通量筛选的需要,基质辅助激光解吸离子化-傅立叶变换离子回旋共振质谱(MALDI-FT ICR MS)由于其高分辨率,高通量和高灵敏度而具有极大的优势,简化繁琐的样品处理步骤,FTMS的高分辨率使我们能够检测复杂样本中质荷比十分接近的化合物。MALDI-FT ICR MS已被广泛应用于各种生物样本中内源性物质的定性和定量分析。The analysis methods of alcohols in biological samples (such as urine, hair, cells) are mainly high-performance liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS), but the pretreatment is complicated and requires separation Purification cannot meet the needs of high-throughput screening. Matrix-assisted laser desorption ionization-Fourier transform ion cyclotron resonance mass spectrometry (MALDI-FT ICR MS) has great advantages due to its high resolution, high throughput and high sensitivity. Simplifying tedious sample processing steps, the high resolution of FTMS enables us to detect compounds with very close mass-to-charge ratios in complex samples. MALDI-FT ICR MS has been widely used in the qualitative and quantitative analysis of endogenous substances in various biological samples.
在已有报道的的生物样本中醇类化合物的分析方法中,醇类化合物由于其较弱的质子亲和力和较弱的酸性,不易电离,在MALDI和ESI中信号较弱,灵敏度较低,且易被其他易电离的物质抑制。为了提高其质谱响应,已有各种不同的衍生化试剂被开发出,甜菜醛(参见Wu,C.P.;Ifa,D.R.;Manicke,N.E.;Cooks,R.G.Anal.Chem.2009,81,7618–7624.),2-吡啶甲酸(参见Higashi,T.;Shibayama,Y.J.;Shimada,K.J.Chromatogr.B2007,846,195-201.),2-氨基吡嗪(Analyst,2013,138,6270-6276)和丹磺酰氯(参见Tang,Z.M.;Peter Guengerich,F.Anal.Chem.2010,82,7706–7712.)被用于衍生化醇类化合物。但这些方法都存在缺点,包括前处理较复杂,过量的衍生化试剂需要除去,衍生化试剂本身有较强的离子化效率,会抑制待测物的检测。In the reported analysis methods of alcohols in biological samples, alcohols are not easy to ionize due to their weaker proton affinity and weaker acidity, and the signals in MALDI and ESI are weaker and the sensitivity is lower. Easily inhibited by other ionizable substances. In order to improve its mass spectral response, various derivatization reagents have been developed, betaine aldehyde (see Wu, C.P.; Ifa, D.R.; Manicke, N.E.; Cooks, R.G. Anal. Chem. 2009, 81, 7618–7624. ), 2-pyridinecarboxylic acid (see Higashi, T.; Shibayama, Y.J.; Shimada, K.J. Chromatogr. B2007, 846, 195-201.), 2-aminopyrazine (Analyst, 2013, 138, 6270-6276) and dansyl chloride (See Tang, Z.M.; Peter Guengerich, F. Anal. Chem. 2010, 82, 7706-7712.) was used to derivatize alcohols. However, these methods have disadvantages, including complex pretreatment, excess derivatization reagents need to be removed, and derivatization reagents themselves have strong ionization efficiency, which will inhibit the detection of analytes.
发明内容Contents of the invention
本发明要解决的问题是:提供一种基于喹啉羧酸的基质衍生化方法结合MALDI-FT ICR MS用于定性分析生物样本中醇类化合物的方法,进一步说是一种通过靶上酯化反应,将这些醇类化合物转化为喹啉酯,过量的试剂发挥基质的作用,这样可以极大地提高目标化合物在随后基质辅助激光解吸离子化-傅立叶变换质谱分析中的分析灵敏度和特异性,无须复杂的样品前处理过程,用于高通量定性分析生物体样本中的醇类化合物,为一种快速、高效、灵敏的分析方法,为进一步研究该类化合物在体内含量变化与生理功能、疾病的关系奠定基础。The problem to be solved by the present invention is to provide a method for the qualitative analysis of alcohol compounds in biological samples based on a quinoline carboxylic acid-based matrix derivatization method combined with MALDI-FT ICR MS, and further to say that it is a method through target esterification reaction to convert these alcohol compounds into quinoline esters, and the excess reagent acts as a matrix, which can greatly improve the analytical sensitivity and specificity of the target compound in the subsequent matrix-assisted laser desorption ionization-Fourier transform mass spectrometry analysis, without the need for The complex sample pretreatment process is used for high-throughput qualitative analysis of alcohol compounds in biological samples. It is a fast, efficient and sensitive analysis method for further research on the content changes of such compounds in the body and their physiological functions and diseases relationship lays the foundation.
为实现上述目的,本发明提供了一种生物样品中醇类化合物的分析方法,其包括如下步骤:In order to achieve the above object, the present invention provides a method for analyzing alcohol compounds in biological samples, which comprises the following steps:
将经过前处理的样品用有机溶剂萃取后,取有机层进行干燥后加入喹啉羧酸的乙腈溶液以及碳酰氯的二氯甲烷溶液,得到反应液;After the pretreated sample is extracted with an organic solvent, the organic layer is taken and dried, and then an acetonitrile solution of quinolinecarboxylic acid and a methylene chloride solution of carbonyl chloride are added to obtain a reaction solution;
将所述反应液点样0.5~1μL于激光解析-傅立叶变换离子回旋共振质谱分析仪的靶上,在15~40℃下反应30~60分钟,以过量的喹啉羧酸作为基质进行基质辅助激光解析-傅立叶变换离子回旋共振质谱分析,所述喹啉羧酸与待测的醇类化合物的摩尔比为20:1-50:1;Spot 0.5-1 μL of the reaction solution on the target of the laser analysis-Fourier transform ion cyclotron resonance mass spectrometer, react at 15-40°C for 30-60 minutes, and use excess quinoline carboxylic acid as the matrix for matrix-assisted Laser analysis-Fourier transform ion cyclotron resonance mass spectrometry analysis, the molar ratio of the quinoline carboxylic acid to the alcohol compound to be measured is 20:1-50:1;
通过对比高分辨数据分析图谱,获得醇类化合物的定性结果;By comparing the high-resolution data analysis spectrum, the qualitative results of alcohol compounds are obtained;
其中,所述样品为含醇类化合物的生物体物质,所述醇类化合物为胆固醇、真菌麦角甾醇、雄酮、维生素D3、胆甾烷醇、脱氢胆固醇、豆甾醇、脱氢采油甾醇、羊毛甾醇中的一种。Wherein, the sample is a biological substance containing alcohol compounds, and the alcohol compounds are cholesterol, fungal ergosterol, androsterone, vitamin D3, cholesterol, dehydrocholesterol, stigmasterol, dehydrooleosterol, A type of lanosterol.
本发明的原理是:使喹啉羧酸与醇类化合物的发生化学反应,利用反应产物进行经基质辅助激光解析-傅立叶变换离子回旋共振质谱分析醇类化合物的喹啉羧酸衍生产物。反应式如图1所示。The principle of the invention is: chemically reacting quinoline carboxylic acid and alcohol compound, using the reaction product to analyze the quinoline carboxylic acid derivative product of the alcohol compound through matrix-assisted laser analysis-Fourier transform ion cyclotron resonance mass spectrometry. The reaction formula is shown in Figure 1.
作为优选方案,所述喹啉羧酸的乙腈溶液中,喹啉羧酸的浓度为2~5mg/mL,体积50-100μL。As a preferred version, in the acetonitrile solution of quinoline carboxylic acid, the concentration of quinoline carboxylic acid is 2-5 mg/mL, and the volume is 50-100 μL.
作为优选方案,所述喹啉羧酸为喹啉-3-羧酸、喹啉-4-羧酸、喹啉-5-羧酸、喹啉-6-羧酸、喹啉-7-羧酸或喹啉-8-羧酸。As a preferred version, the quinoline carboxylic acid is quinoline-3-carboxylic acid, quinoline-4-carboxylic acid, quinoline-5-carboxylic acid, quinoline-6-carboxylic acid, quinoline-7-carboxylic acid or quinoline-8-carboxylic acid.
作为优选方案,所述碳酰氯的二氯甲烷溶液中,碳酰氯的体积分数为10~40%,体积50-100μL。As a preferred solution, in the methylene chloride solution of phosgene, the volume fraction of phosgene is 10-40%, and the volume is 50-100 μL.
作为优选方案,所述样品的前处理过程为:将样品加入1~2mL体积比1:1的氢氧化钾/乙醇溶液,在60~70℃下皂化水解1~2h。As a preferred solution, the pretreatment process of the sample is: add 1-2 mL of potassium hydroxide/ethanol solution with a volume ratio of 1:1 to the sample, and saponify and hydrolyze it at 60-70°C for 1-2 hours.
作为优选方案,所述基质辅助激光解析-傅立叶变换离子回旋共振质谱分析的条件是:激光能量20~30%,扫描范围:m/z 100~1500,频率:1000Hz,斑点直径500~1000μm,数据采集均在正离子模式下进行;子离子扫描条件:碰撞能10-30eV。As a preferred solution, the conditions for the matrix-assisted laser analysis-Fourier transform ion cyclotron resonance mass spectrometry analysis are: laser energy 20-30%, scanning range: m/z 100-1500, frequency: 1000 Hz, spot diameter 500-1000 μm, data Acquisition was carried out in positive ion mode; product ion scanning conditions: collision energy 10-30eV.
作为优选方案,所述样品为毛发或酵母细胞。As a preferred solution, the sample is hair or yeast cells.
与现有技术相比,本发明具有如下的有益效果:Compared with the prior art, the present invention has the following beneficial effects:
1、用于在MALDI靶上特异性衍生化醇羟基,在质谱分析的过程中更有针对性,提高待测物的离子化效率,增强了分析灵敏度(检测限0.2-0.5ng/mL);1. It is used to specifically derivatize alcoholic hydroxyl groups on the MALDI target, which is more targeted in the process of mass spectrometry analysis, improves the ionization efficiency of the analyte, and enhances the analytical sensitivity (detection limit 0.2-0.5ng/mL);
2、靶上反应后无需复杂的样品前处理过程,反应后直接分析,实现高通量分析,操作简便,高分辨率使我们能够检测复杂样本中质荷比十分接近的化合物;2. No complicated sample pretreatment process is required after the on-target reaction, and the reaction is directly analyzed to achieve high-throughput analysis. The operation is simple and the high resolution enables us to detect compounds with very close mass-to-charge ratios in complex samples;
3、此发明所用的衍生化试剂简单,易得,标记部分相对较小(173Da),结构也相对简单,性质比较稳定,在质谱子离子扫描分析中碰撞能作用下可产生脱去一分子喹啉羧酸酯碎片离子[M-172]+,提高选择性,有利于增强定性分析的准确性。3, the used derivatization reagent of this invention is simple, easy to get, and labeling part is relatively small (173Da), and structure is also relatively simple, and property is relatively stable, can produce and take off a molecular quinolone under the impact of collision energy in mass spectrometry product ion scanning analysis. Phenyl carboxylate fragment ion [M-172]+, which improves selectivity and helps to enhance the accuracy of qualitative analysis.
本发明被应用于定性分析各类生物样品中的醇类化合物,胆固醇、胆甾烷醇、真菌麦角甾醇,雄酮,维生素D3,脱氢胆固醇、豆甾醇、谷甾醇、菜油甾醇,脱氢菜油甾醇、羊毛甾醇等。通过此方法可以实现快速、高效、灵敏的检测醇类化合物。The present invention is applied to the qualitative analysis of alcohol compounds in various biological samples, such as cholesterol, cholestanol, fungal ergosterol, androsterone, vitamin D3, dehydrocholesterol, stigmasterol, sitosterol, campesterol, dehydrogenated rapeseed oil Sterols, lanosterol, etc. Through this method, rapid, efficient and sensitive detection of alcohol compounds can be realized.
附图说明Description of drawings
通过阅读参照以下附图对非限制性实施例所作的详细描述,本发明的其它特征、目的和优点将会变得更明显:Other characteristics, objects and advantages of the present invention will become more apparent by reading the detailed description of non-limiting embodiments made with reference to the following drawings:
图1为本发明的中醇类化合物与喹啉羧酸的化学反应式;Fig. 1 is the chemical reaction formula of middle alcohol compound of the present invention and quinoline carboxylic acid;
图2为胆固醇标准品经喹啉-3-羧酸/碳酰氯靶上酯化反应后的基质辅助激光解析-傅立叶变换离子回旋共振质谱(MALDI-FT ICR MS)图谱,母离子m/z 542.4,子离子m/z 369.4;Figure 2 is the matrix-assisted laser desorption-Fourier transform ion cyclotron resonance mass spectrometry (MALDI-FT ICR MS) spectrum of the cholesterol standard after the esterification reaction on the quinoline-3-carboxylic acid/carbonyl chloride target, the parent ion m/z 542.4 , product ion m/z 369.4;
图3为生物样本中醇类化合物的靶上衍生化-基质辅助激光解析-傅立叶变换离子回旋共振质谱(MALDI-FT ICR MS)定性分析过程示意图;Figure 3 is a schematic diagram of the qualitative analysis process of alcohol compounds in biological samples by derivatization-matrix-assisted laser analysis-Fourier transform ion cyclotron resonance mass spectrometry (MALDI-FT ICR MS);
图4为毛发样本未经衍生化的MALDI-FT ICR MS图谱;Figure 4 is the underivatized MALDI-FT ICR MS spectrum of the hair sample;
图5为毛发样本经喹啉-3-羧酸/碳酰氯靶上衍生化后的MALDI-FT ICR MS图谱,m/z 542.4。Figure 5 is the MALDI-FT ICR MS spectrum of the hair sample derivatized on the quinoline-3-carboxylic acid/carbonyl chloride target, m/z 542.4.
图6为酵母细胞未经衍生化的MALDI-FT ICR MS图谱;Figure 6 is the underivatized MALDI-FT ICR MS spectrum of yeast cells;
图7为酵母细胞经喹啉-3-羧酸/碳酰氯靶上衍生化后的MALDI-FT ICR MS图谱,m/z 542。Figure 7 is the MALDI-FT ICR MS spectrum of yeast cells derivatized on the quinoline-3-carboxylic acid/carbonyl chloride target, m/z 542.
具体实施方式Detailed ways
下面结合具体实施例对本发明进行详细说明。以下实施例将有助于本领域的技术人员进一步理解本发明,但不以任何形式限制本发明。应当指出的是,对本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进。这些都属于本发明的保护范围。The present invention will be described in detail below in conjunction with specific embodiments. The following examples will help those skilled in the art to further understand the present invention, but do not limit the present invention in any form. It should be noted that those skilled in the art can make several modifications and improvements without departing from the concept of the present invention. These all belong to the protection scope of the present invention.
本发明的喹啉羧酸以及待测的醇类化合物的结构式如1所示,本发明的工艺流程如图3所示。The structural formula of the quinoline carboxylic acid of the present invention and the alcohol compound to be tested is shown in 1, and the process flow of the present invention is shown in Figure 3.
实施例1毛发样中胆固醇的定性分析Qualitative Analysis of Cholesterol in Example 1 Hair Sample
操作步骤如下:The operation steps are as follows:
毛发用蒸馏水,二氯甲烷和异丙醇洗涤,50~60℃干燥,毛发剪成1~2mm,称取0.3~0.4mg,加入1~2mL氢氧化钾:乙醇(体积比1:1),60~70℃皂化水解1~2h,分别加入2.5~5mL的乙醚提取两次,合并有机层后KOH干燥,氮气吹干,加入50~100μL 2~5mg/mL的喹啉-3-羧酸/乙腈溶液,再与50~100μL 10~40v/v%的碳酰氯/二氯甲烷溶液混合;反应液点样0.5~1μL于靶上,15~40℃反应30~60分钟,基质辅助激光解析-傅立叶变换离子回旋共振质谱(MALDI-FT ICR MS)分析,谱图如图2所示,毛发样本衍生化前后的MALDI-FT ICR MS图谱如附图4、5所示。可以看出毛发样品经过反应后,可以得到胆固醇的衍生化产物质谱峰m/z 542.4,而未经过反应的毛发样品中,未检测出胆固醇的峰。Wash the hair with distilled water, dichloromethane and isopropanol, dry at 50-60°C, cut the hair into 1-2 mm, weigh 0.3-0.4 mg, add 1-2 mL of potassium hydroxide: ethanol (volume ratio 1:1), Saponify and hydrolyze at 60-70°C for 1-2 hours, add 2.5-5 mL of diethyl ether to extract twice, combine the organic layers, dry with KOH, blow dry with nitrogen, add 50-100 μL of 2-5 mg/mL quinoline-3-carboxylic acid/ Mix acetonitrile solution with 50-100μL 10-40v/v% phosgene/dichloromethane solution; spot 0.5-1μL of the reaction solution on the target, react at 15-40°C for 30-60 minutes, matrix-assisted laser analysis- Fourier transform ion cyclotron resonance mass spectrometry (MALDI-FT ICR MS) analysis, the spectrum is shown in Figure 2, and the MALDI-FT ICR MS spectrum of the hair sample before and after derivatization is shown in Figures 4 and 5. It can be seen that after the hair sample is reacted, the mass spectrum peak of the derivatized product of cholesterol can be obtained at m/z 542.4, while in the unreacted hair sample, no cholesterol peak is detected.
实施例2酵母细胞中麦角甾醇的定性分析Qualitative analysis of ergosterol in embodiment 2 yeast cells
酵母细胞称取200-500mg,加入1~2mL氢氧化钾:乙醇(体积比1:1),60~70℃皂化水解1~2h,分别加入2.5~5mL的乙醚提取两次,合并有机层后KOH干燥,氮气吹干,加入50~100μL 2-5mg/mL的喹啉-3-羧酸/乙腈溶液,再与50~100μL10~40v/v%的碳酰氯/二氯甲烷溶液混合;反应液点样0.5~1μL于靶上,15~40℃反应30~60分钟,基质辅助激光解析-傅立叶变换离子回旋共振质谱(MALDI-FT ICR MS)分析。Weigh 200-500 mg of yeast cells, add 1-2 mL of potassium hydroxide: ethanol (volume ratio 1:1), saponify and hydrolyze at 60-70 °C for 1-2 hours, add 2.5-5 mL of ether to extract twice, and combine the organic layers Dry with KOH, dry with nitrogen, add 50-100μL 2-5mg/mL quinoline-3-carboxylic acid/acetonitrile solution, and mix with 50-100μL 10-40v/v% carbonyl chloride/dichloromethane solution; the reaction solution Spot 0.5-1 μL on the target, react at 15-40°C for 30-60 minutes, and analyze by matrix-assisted laser desorption-Fourier transform ion cyclotron resonance mass spectrometry (MALDI-FT ICR MS).
酵母细胞衍生化前后的MALDI-FT ICR MS图谱如附图6、7所示。可以看出酵母细胞样品经过反应后,可以得到麦角甾醇的衍生化产物质谱峰m/z 536.4,而未经过反应的酵母细胞样品中,未检测出麦角甾醇的峰。The MALDI-FT ICR MS spectra of yeast cells before and after derivatization are shown in Figures 6 and 7. It can be seen that after the reaction of the yeast cell sample, the mass spectrum peak of the derivative product of ergosterol m/z 536.4 can be obtained, while the peak of ergosterol was not detected in the unreacted yeast cell sample.
本发明采用高分辨FTMS的准确质量测定技术,以误差小于5ppm为标准,比较图谱中的质荷比与理论的目标化合物衍生化产物的准确质荷比,并进一步推算出目标化合物的衍生化产物的元素组成。实验中对胆固醇衍生产物和麦角甾醇衍生产物进行准确质量测定,通过比较毛发样本或酵母细胞样本衍生化后的高分辨质谱数据,从而得到相应的元素组成,对毛发中的胆固醇和酵母细胞中的麦角甾醇进行定性分析,从表1中看出,衍生产物的理论质荷比与实验值误差在5ppm以内。The present invention adopts the accurate mass measurement technology of high-resolution FTMS, takes the error less than 5ppm as the standard, compares the mass-to-charge ratio in the spectrum with the accurate mass-to-charge ratio of the derivatized product of the target compound, and further calculates the derivatized product of the target compound element composition. In the experiment, accurate mass determination of cholesterol-derived products and ergosterol-derived products was carried out. By comparing the high-resolution mass spectrometry data after derivatization of hair samples or yeast cell samples, the corresponding elemental composition was obtained. Ergosterol is carried out qualitative analysis, find out from table 1, the theoretical mass-to-charge ratio of derivative product and experimental value error are within 5ppm.
表1.毛发和酵母细胞经过靶上衍生反应和质谱检测后所得甾醇分析结果Table 1. Analysis results of sterols in hair and yeast cells after on-target derivatization and mass spectrometry detection
以上对本发明的具体实施例进行了描述。需要理解的是,本发明并不局限于上述特定实施方式,本领域技术人员可以在权利要求的范围内做出各种变形或修改,这并不影响本发明的实质内容。Specific embodiments of the present invention have been described above. It should be understood that the present invention is not limited to the specific embodiments described above, and those skilled in the art may make various changes or modifications within the scope of the claims, which do not affect the essence of the present invention.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510164576.6A CN104865307A (en) | 2015-04-08 | 2015-04-08 | Analysis method for alcohol compound in biological sample |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510164576.6A CN104865307A (en) | 2015-04-08 | 2015-04-08 | Analysis method for alcohol compound in biological sample |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104865307A true CN104865307A (en) | 2015-08-26 |
Family
ID=53911286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510164576.6A Pending CN104865307A (en) | 2015-04-08 | 2015-04-08 | Analysis method for alcohol compound in biological sample |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104865307A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108051526A (en) * | 2018-01-11 | 2018-05-18 | 哈尔滨工业大学 | A kind of method of PREPOD pollutants in detection environment |
CN113640368A (en) * | 2020-04-27 | 2021-11-12 | 株式会社岛津制作所 | Methods for structural analysis of organic compounds |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102175750A (en) * | 2011-02-25 | 2011-09-07 | 中国科学院上海有机化学研究所 | Method for analyzing biological samples by using matrix assisted laser desorption ionization-Fourier transform ion cyclotron resonance mass spectra |
CN102967647A (en) * | 2012-11-15 | 2013-03-13 | 中国科学院上海有机化学研究所 | Electrospray ionization-quadrupole-time-of-flight mass spectrometry analyzing method of sterol contained in edible oil |
-
2015
- 2015-04-08 CN CN201510164576.6A patent/CN104865307A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102175750A (en) * | 2011-02-25 | 2011-09-07 | 中国科学院上海有机化学研究所 | Method for analyzing biological samples by using matrix assisted laser desorption ionization-Fourier transform ion cyclotron resonance mass spectra |
CN102967647A (en) * | 2012-11-15 | 2013-03-13 | 中国科学院上海有机化学研究所 | Electrospray ionization-quadrupole-time-of-flight mass spectrometry analyzing method of sterol contained in edible oil |
Non-Patent Citations (2)
Title |
---|
TATSUYA HIGASHI, ET AL: "Determination of salivary dehydroepiandrosterone using liquid chromatography–tandem mass spectrometry combined with charged derivatization", 《JOURNAL OF CHROMATOGRAPHY B》 * |
梅苏宁: "喹啉和吡啶2位羧酸及其甲酯的合成研究", 《中国优秀硕士学位论文全文数据库工程科技I辑》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108051526A (en) * | 2018-01-11 | 2018-05-18 | 哈尔滨工业大学 | A kind of method of PREPOD pollutants in detection environment |
CN113640368A (en) * | 2020-04-27 | 2021-11-12 | 株式会社岛津制作所 | Methods for structural analysis of organic compounds |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | The application of ion mobility mass spectrometry to metabolomics | |
Xia et al. | Chemical derivatization strategy for mass spectrometry‐based lipidomics | |
Pozo et al. | Comparison between triple quadrupole, time of flight and hybrid quadrupole time of flight analysers coupled to liquid chromatography for the detection of anabolic steroids in doping control analysis | |
Peng et al. | Liquid–liquid extraction combined with differential isotope dimethylaminophenacyl labeling for improved metabolomic profiling of organic acids | |
Liu et al. | Isomer-specific profiling of N-glycans derived from human serum for potential biomarker discovery in pancreatic cancer | |
CN102175750A (en) | Method for analyzing biological samples by using matrix assisted laser desorption ionization-Fourier transform ion cyclotron resonance mass spectra | |
Raro et al. | Potential of atmospheric pressure chemical ionization source in gas chromatography tandem mass spectrometry for the screening of urinary exogenous androgenic anabolic steroids | |
Hu et al. | Use of ammonium sulfite as a post-column derivatization reagent for rapid detection and quantification of aldehydes by LC-MS | |
Mouskeftara et al. | Analysis of urinary organic acids by gas chromatography tandem mass spectrometry method for metabolic profiling applications | |
Delgadillo et al. | Sensitive and robust method for anabolic agents in human urine by gas chromatography–triple quadrupole mass spectrometry | |
Kang et al. | On-site testing of multiple drugs of abuse in urine by a miniature dual-LIT mass spectrometer | |
Cao et al. | N-alkylpyridinium quaternization combined with liquid chromatography–electrospray ionization-tandem mass spectrometry: A highly sensitive method to quantify fatty alcohols in thyroid tissues | |
Borisov et al. | Suitable in-situ derivatization of alcohols by reaction with basic amines in direct analysis in real time mass spectrometry | |
Qiu et al. | Multi-dimensional characterization and identification of sterols in untargeted LC-MS analysis using all ion fragmentation technology | |
Fang et al. | Quadrupole-linear ion trap tandem mass spectrometry system for clinical biomarker analysis | |
Song et al. | Quantitative MALDI-MS assay of steroid hormones in plasma based on hydroxylamine derivatization | |
Gu et al. | Simultaneous multiplexed quantification and C= C localization of fatty acids with LC-MS/MS using isobaric multiplex reagents for carbonyl-containing compound (SUGAR) tags and C= C epoxidation | |
Wang et al. | Mass spectrometry based on chemical derivatization has brought novel discoveries to lipidomics: A comprehensive review | |
CN104865307A (en) | Analysis method for alcohol compound in biological sample | |
Kang et al. | On-site quantitation of morphine in urine by fast derivatization and miniature mass spectrometry analysis | |
Swanson et al. | Analysis of unknown fentanyl analogs using high resolution mass spectrometry with mass defect filtering | |
CN102967647B (en) | The electrospray ionization-quadrupolmassme-of-flight Tandem Mass Spectrometry Analysis method of sterol in edible oil | |
Duan et al. | Derivatization of β‐dicarbonyl compound with 2, 4‐dinitrophenylhydrazine to enhance mass spectrometric detection: application in quantitative analysis of houttuynin in human plasma | |
Wachełko et al. | New approach for barbiturates, phenytoin, methyprylon and glutethimide determination and fragmentation (UHPLC-MS/MS) | |
CN111175410A (en) | Application of N-methylphenethylamine and its isotopic reagents in the detection of carboxyl compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150826 |